Back to search

Peptide record

TPDB10003

Antibacterial Antifungal Hemolysis Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB10003
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP APD_complete PD_Hemolysis ToxinPred 3.0
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
FLRSLLRGAKAIYRGARAGWRG
Physicochemical Analysis
C112H183N39O25
NDCEQHMPTV
R
2475.93
12.58
6
0
11
+6
-1.38
-0.232
89.09
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
6990
282.32
2
Residue Composition
number
4
A
5
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
1
I
3
L
1
K
0
M
1
F
0
P
1
S
0
T
1
W
1
Y
0
V
Amino Acid Distribution
A: 4 R: 5 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 3 K: 1 M: 0 F: 1 P: 0 S: 1 T: 0 W: 1 Y: 1 V: 0
Chemical Descriptors
22
C112H183N39O25
2475.93
12.58
+6
-1.38
-0.232
Evidence Records 19 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4.68 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
Active against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml
Evidence 2 Activity

Activity

MIC
Antibacterial
37.5 µg/mL

Target

Pseudomonas aeruginosa ATCC10662

Source & Reference

dbAMP

Other

Active against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or
Evidence 3 Activity

Activity

MIC
Antibacterial
18.75 µg/mL

Target

A. baumannii Clinical isolate

Source & Reference

dbAMP

Other

ve against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (
Evidence 4 Activity

Activity

MIC
Antibacterial
4.68 µg/mL

Target

Staphylococcus aureus ATCC 25923 or MRSA

Source & Reference

dbAMP

Other

CC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-
Evidence 5 Activity

Activity

MIC
Antibacterial
1.17 µg/mL

Target

Staphylococcus epidermidis ATCC 1435

Source & Reference

dbAMP

Other

isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.3
Evidence 6 Activity

Activity

MIC
Antibacterial
4.68-9.37 µg/mL

Target

Candida albicans

Source & Reference

dbAMP

Other

MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 u
Evidence 7 Activity

Activity

MIC
Antibacterial
4.68-9.37 µg/mL

Target

C. tropicalis

Source & Reference

dbAMP

Other

ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 ug/ml). Updated 7/2021
Evidence 8 Activity

Activity

MIC
Antibacterial
>150 µg/mL

Target

C.glabrata clinical isolate

Source & Reference

dbAMP

Other

ains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 ug/ml). Updated 7/2021
Evidence 9 Activity

Activity

MIC
Antifungal
4.68 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
Active against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml
Evidence 10 Activity

Activity

MIC
Antifungal
37.5 µg/mL

Target

Pseudomonas aeruginosa ATCC10662

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Active against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or
Evidence 11 Activity

Activity

MIC
Antifungal
18.75 µg/mL

Target

A. baumannii Clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ve against E. coli ATCC 25922 (MIC 4.68 ug/mL), P. aeruginosa ATCC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (
Evidence 12 Activity

Activity

MIC
Antifungal
4.68 µg/mL

Target

Staphylococcus aureus ATCC 25923 or MRSA

Source & Reference

dbAMP CAFPdb Antifungipept

Other

CC10662 (MIC 37.5 ug/ml), A. baumannii Clinical isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-
Evidence 13 Activity

Activity

MIC
Antifungal
1.17 µg/mL

Target

Staphylococcus epidermidis ATCC 1435

Source & Reference

dbAMP CAFPdb Antifungipept

Other

isolate (MIC 18.75 ug/ml), Gram+ bacteria S. aureus ATCC 25923 or MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.3
Evidence 14 Activity

Activity

MIC
Antifungal
4.68-9.37 µg/mL

Target

Candida albicans

Source & Reference

dbAMP CAFPdb Antifungipept

Other

MRSA (MIC 4.68 ug/ml), S. epidermidis ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 u
Evidence 15 Activity

Activity

MIC
Antifungal
4.68-9.37 µg/mL

Target

C. tropicalis

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ATCC 1435 (MIC 1.17 ug/ml), yeast clinical strains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 ug/ml). Updated 7/2021
Evidence 16 Activity

Activity

MIC
Antifungal
>150 µg/mL

Target

C.glabrata clinical isolate

Source & Reference

dbAMP CAFPdb Antifungipept

Other

ains C. albicans (MIC 4.68-9.37 ug/ml) and C. tropicalis (MIC 4.68-9.37 ug/ml). Inactive: C.glabrata clinical isolate (MIC>150 ug/ml). Updated 7/2021
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
57 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 57 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Identification of novel antimicrobial peptide from Asian sea bass (Lates calcarifer) by in silico and activity characterization. | PLoS One | 2018
Evidence 18 Activity

Activity

65% Hemolysis
Toxicity
75 µg/mL
Hemolytic Cytotoxic
65% Hemolysis | 75 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Identification of novel antimicrobial peptide from Asian sea bass (Lates calcarifer) by in silico and activity characterization. | PLoS One | 2018
Evidence 19 Hemolysis

Source & Reference

APD_complete PD_Hemolysis
APD_complete PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation.